40results about How to "Easy to reconstitute" patented technology

The object of the invention is to provide an immunological reconstitution promoter or a prophylactic agent for infections for use in allogeneic hematopoietic stem cell transplantation therapy for tumors. The promoter or prophylactic agent enables the amelioration of delayed immune reconstitution or the prevention of infection following transplantation, while maintaining the GVT effect of allogeneic hematopoietic stem cell transplantation. Specifically, in a transplant patient in whom immune reconstitution is delayed, such reconstitution can be promoted by administering, at an early stage following transplantation, a substance capable of depleting CD4+ cells. Early completion of infection management in the patient and improvement in the survival rate are anticipated as a result. In addition, the risk of complications associated with allogeneic hematopoietic stem cell transplantation is reduced, enabling more widespread use of this therapy.

This invention concerns novel methods of enhancing the solubility of a compound. Compositions prepared using such methods are also disclosed. Compositions prepared using the methods have various advantages over conventionally known compositions.

The invention discloses a preparation method of urchin-like nano gold particles. The preparation method is characterized by mainly comprising the following steps: adding a chloroauric acid solution into an N-(2-ethoxy) piperazine-N'-2-ethanesulfonic acid solution, carrying out full and uniform stirring and mixing, slowly stirring the solution till the solution turns from colorless transparency into a dark blue color, stopping stirring, stewing for 10 to 25 minutes to fully complete the reaction, and then adding citric acid or potassium carbonate to adjust the pH value to be 5.5 to 8.5. Compared with the prior art, the preparation method has the advantages of quickness, no need of gold seeds, green synthesis and the like.

The invention discloses a highly water-soluble porcine small intestine digestive enzyme powder and a preparation method thereof. The pig small intestine digestive enzyme powder is prepared according to a method comprising the following steps: 1) collecting intestinal chyme from the small intestines of several pigs and mixing them uniformly, and then centrifuging the mixed intestinal chyme 1. Collect the supernatant 1; 2) Evaporate and concentrate the supernatant 1 to obtain concentrated intestinal juice; centrifuge the concentrated intestinal juice 2 to collect the supernatant 2; 3) Transfer the supernatant 2 Put it in a container placed in an ice-water bath, and add mannitol therein, after stirring and dissolving, then add ethanol solution, stir evenly and let it stand; then carry out centrifugation 3, collect the precipitate; 4) add deionized water to the precipitate , and stirred and ultrasonically dissolved, and then centrifuged 4 to collect the supernatant 3; the supernatant 3 was freeze-dried to obtain. The intestinal digestive enzyme powder prepared by the invention improves the specific activity of the digestive enzyme, reduces the impurity content and improves the solubility of the digestive enzyme.

The invention discloses a micro-balloon injection for a pharmaceutical composition of cefmenoxime hydrochloride / anhydrous sodium carbonate, which is characterized by comprising cefmenoxime hydrochloride, anhydrous sodium carbonate, polylactic acid- polyethylene glycol block copolymer, poloxamer 188, glycerol and mannitol. The optimal scheme of the invention is the micro-balloon injection for the pharmaceutical composition of cefmenoxime hydrochloride / anhydrous sodium carbonate, which is characterized by comprising 1 part of cefmenoxime hydrochloride, 0.12-0.18 part of anhydrous sodium carbonate, 1.2-4.5 parts of polylactic acid- polyethylene glycol block copolymer, 0.8-2 part(s) of poloxamer 188, 0.5-1 part of glycerol and 3-6 parts of mannitol. Compared with the prior art, the micro-balloon injection for the pharmaceutical composition of cefmenoxime hydrochloride / anhydrous sodium carbonate prepared by the invention has high stability, the preparation process is simple and is suitable for industrial production, and has high encapsulation efficiency. As anhydrous sodium carbonate is used as a latent solvent, the re-dissolution is good, and has an appropriate slow-release effect.

The present invention relates to a new coronavirus single-chain antibody, a quality control product and a preparation method, which include a light chain variable region and a heavy chain variable region in sequence from the N segment to the C terminal, and the amino acid sequence of the light chain variable region is as shown in SEQ As shown in ID NO:1, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:2. The novel coronavirus single-chain antibody of the present invention has high sensitivity and good stability, and is very suitable for the preparation of quality control products. Moreover, on the basis of this variable region sequence, further use gene recombination technology to construct a human-mouse chimeric IgM antibody without a CH1 fragment, thereby improving molecular stability and specific binding ability. The novel coronavirus single-chain antibody prepared by the invention can be applied to a chemiluminescence platform for quality control detection, can effectively measure activity, and can overcome the defects of poor detection sensitivity and low specificity of general 2019‑nCoV IgM antibodies.

The invention discloses a flucloxacilin sodium liposome injection. The flucloxacilin sodium liposome injection is mainly prepared from flucloxacilin sodium, polysorbate 80, gylcocholic acid sodium salt, gelatin, glycerol and sodium chloride; the defect of instability of the flucloxacilin preparation is overcome; and the liposome injection is prepared by protecting flucloxacilin sodium package by using liposome and then performing spray drying and aseptic subpackage, so that the stability of the flucloxacilin sodium is greatly increased, the preparation process is simple, yield is high, and solubility is high. The product quality of the preparation is improved and the toxic and side effects are reduced.

The invention relates to an officinal composition of vidarabine monophosphate for injection, wherein the main active components of the composition comprise vidarabine monophosphate and lysine.

The invention discloses cefamandole nafate / anhydrous sodium carbonate medicinal composition microsphere injection, which is characterized by consisting of cefamandole nafate, anhydrous sodium carbonate, PGLA, Tween-80, propylene glycol and glucose. The invention adopts the preferable scheme that the cefamandole nafate / anhydrous sodium carbonate medicinal composition microsphere injection is characterized by comprising the following components in part by weight: 1 part of cefamandole nafate, 0.08 to 0.12 part of anhydrous sodium carbonate, 1.5 to 6 parts of PGLA, 0.2 to 2 parts of Tween-80, 0.3 to 3 parts of propylene glycol and 2 to 8 parts of glucose. Compared with the prior art, the prepared cefamandole nafate microspheres have stability, a preparation process is simple and suitable forindustrialized production, the entrapment rate is high, and the anhydrous sodium carbonate used as a co-solvent has good resolution and proper slow-release effect.

The present invention relates to a Clofarabine freeze drying powder and the preparation method, which comprises Clofarabine and at least one biological acceptable excipient. Wight ratio of the Clofarabine and the excipient is from one to 10 till one to 50. The excipient is selected from one kind of mannitol and lactose. The optional choice is the mannitol. The preparation method is as following. The Clofarabine is melted with the injection water and the excipient is added. Followed by well mixing , filtration, packaging, adding stopper and loading in the plate. The freeze dryer is opened in advance. The platelayer is cooled with the heat conduction oil until temperature of the platelayer increases till minus 40 DEG Cto minus 50 DEG C. The Clofarabine solution packaged in the sterile silinbottle can be sent to the freeze dryer quickly.The box door is shut and the plate temperature is kept at minus 40 DEG Cto minus 50 DEG C and the box temperature is decreased. When the sample temperature reaches minus 40 DEG C, The plate cooling is stopped and the condenser is opened. At the same time the product temperature is maintaineed by cooling for 3 hours. When the temperature of the condenser reaches minus 40 DEG, the vacuum system is opened. After temperature holding, four steps of heating, sublimation, drying, plugging, box pressing and opening sealing can be started.